[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"human-immunodeficiency-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:human-immunodeficiency-virus":24},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,47,76,96,107,136,161,189,228,254,280,305,332,357,384,407,431,453,476,502,524,547,577,604,623],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053304","molecular-characterization-of-viral-associated-tumors-tumors-occurring-in-the-setting-of-hiv-or-other-immune-disorders-and-castleman-disease-100053304",false,"NCT03300830","Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease","* INCLUSION CRITERIA:\n\nParticipants with one or more of the following:\n\n* HIV or other acquired immunodeficiency and cancer\n* Viral-associated cancer or cancer hypothesized to be caused by a virus\n* HIV-negative participants with cancer that commonly occurs in people with HIV\n\n  --KSHV-associated malignancy or related diseases, such as Multicentric Castleman Disease (MCD)\n* A malignancy hypothesized to be caused by an endogenous retrovirus\n* Idiopathic Castleman disease\n\nCancer diagnoses will be confirmed by the NCI Laboratory of Pathology (LP). A biopsy will be collected if sufficient archival tissue is not available.\n\n* Age \\>=18 years.\n* ECOG performance status \\\u003C=2 (Karnofsky \\>=60%) if biopsy to be performed is solely for the purposes of this protocol. Any ECOG performance status will be allowed if biopsy required for participant care or another NIH protocol that allows lower performance status or if enrollment on this protocol is only for the purposes of studying tissue that has already been collected.\n* Participants must have signed or be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects. Telephone consent for use of archival tissue or tissue collected on another protocol or standard participant care will be permitted.\n* Co-enrollment on other HAMB, NCI, or NIH protocols is allowed\n\nEXCLUSION CRITERIA:\n\n* Inability to provide informed consent.\n* Pregnancy: Pregnant women will not be allowed to participate in this study because there is not a potential benefit.","ALL","18 Years",{"count":19,"type":20},280,"ESTIMATED","OBSERVATIONAL","Background:\n\nA person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes. Genome sequencing allows researchers to find variations in genes. Some of these are normal and are not known to cause disease. Some variants are known to cause or affect diseases like cancer. Researchers want to study genetic variants in people with cancer who also have an immunologic disease like HIV.\n\nObjective:\n\nTo study the biology of cancer in order to improve ways to prevent, detect, and treat it.\n\nEligibility:\n\nAdults at least 18 years old with certain cancers and\u002For immunodeficiencies\n\nDesign:\n\nParticipants will be screened with medical history, physical exam, and lab tests.\n\nParticipants will give samples of one or more tissue type.\n\nThey may give blood or urine samples.\n\nResearchers may get samples of tissue when participants have surgery or when the participants are on other protocols in the NCI.\n\nParticipants may have a procedure to have tissue samples removed.\n\nResearchers may collect data from participant medical records.\n\nResearchers will compare the genes in a participant s cancer tissue to their normal tissue. They may use the tissue cells to grow new cells in a lab.\n\nParticipants may be contacted about the results.\n\nThe samples will be stored for future research. No personal data will be kept with them.\n\n...",[24,25,26,27],"Human Immunodeficiency Virus","Castleman's Disease","Kaposi's Sarcoma","Viral-Associated Cancer",[29,27,30,31,32,33],"Immunodeficiency","Kaposi Sarcoma Herpes Virus","Idiopathic Castleman Disease","Endogenous Retroviruses","Natural History","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2017-12-20",{"date":42,"type":20},"2037-06-25",{"name":44,"class":45},"National Cancer Institute (NCI)","NIH",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100579044","phase-1-lenacapavir-intensification-to-disrupt-hiv-reservoirs-in-virologically-suppressed-people-with-hiv-receiving-antiretroviral-therapy-100579044","NCT06819176","Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Able to provide informed consent.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Aged 18 years to 75 years.\n4. In generally good health with an identified primary health care provider for medical management of HIV infection and willing to maintain a relationship with a primary health care provider while participating in the study.\n5. Confirmed HIV-1 infection.\n6. Total HIV DNA reservoir size greater than 300 copies\u002F106 CD4+ T cells.\n7. CD4+ T cell count \\>200 cells\u002Fmm\\^3 at screening.\n8. Documentation of continuous ART treatment \\>3 years with suppression of plasma viral level below the limit of quantitation (\\\u003C40 copies\u002FmL). Individuals with \\\u003C= 2 blips (\\>40 copies\u002FmL) over 48 weeks prior to screening may be included provided they satisfy the following criteria:\n\n   1. The blips are \\\u003C=200 copies\u002FmL.\n   2. Succeeding viral levels return to below the limit of quantification (\\\u003C40 copies\u002FmL) on subsequent testing.\n9. For individuals who can become pregnant (ie, participants who have not been postmenopausal for at least 24 consecutive months, who have had menses within the preceding 24 months, or who have not undergone surgical sterilization, specifically hysterectomy and\u002For bilateral oophorectomy), must have a negative pregnancy test at screening and within 48 hours prior to day 0. Participant-reported history is acceptable as documentation of hysterectomy and bilateral oophorectomy, tubal ligation, tubal micro-inserts, and vasectomy.\n10. Participants who can become pregnant must agree to use 1 acceptable method of contraception when engaging in sexual activities that can result in pregnancy from 10 days prior to the first dose of lenacapavir through study follow up. Acceptable methods of contraception include the following:\n\n    1. Contraceptive subdermal implant.\n    2. Intrauterine device or intrauterine system.\n    3. Combined estrogen and progestogen oral contraceptive.\n    4. Injectable progestogen.\n    5. Contraceptive vaginal ring.\n    6. Percutaneous contraceptive patches.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. History of AIDS-defining illness within 3 years prior to enrollment.\n2. History of systemic corticosteroids (eg, an equivalent dose of prednisone of \\>20 mg daily for \\>14 days), immunosuppressive anti-cancer, interleukins, systemic interferons, systemic chemotherapy, or other medications considered significant by the principal investigator within the last 6 months.\n3. Any clinically significant acute or chronic medical condition (eg, autoimmune diseases, cirrhosis, active malignancy that may require systemic chemotherapy or radiation therapy), other than HIV infection, that in the opinion of the investigator would preclude participation.\n4. Hepatitis B or C infection as indicated by the presence of hepatitis B surface antigen or hepatitis C virus (HCV) RNA in blood.\n\n   NOTE: Participants with a positive test for HCV antibody and a negative test for HCV RNA are eligible.\n5. Pregnancy or lactation.\n6. Any licensed vaccine (eg, hepatitis B, influenza, pneumococcal polysaccharide) received within 2 weeks prior to the study enrollment.\n7. Receipt of other investigational study agents within 28 days of enrollment and at any time during the study, including any experimental non-HIV vaccination within 2 weeks prior to enrollment.\n8. Systemic immunosuppressive medications received within 3 months prior to enrollment. The following are not excluded:\n\n   1. Corticosteroid nasal spray or inhaler.\n   2. Topical corticosteroids for mild, uncomplicated dermatitis.\n   3. Oral\u002Fparenteral corticosteroids administered for non-chronic conditions not expected to recur (length of therapy 10 days, with completion in 30 days prior to enrollment).\n   4. Cyclosporine eye drops\n9. Active drug or alcohol abuse or any other pattern of behavior that, in the opinion of the investigator, would interfere with adherence to study requirements.\n10. Laboratory abnormalities in the parameters listed below:\n\n    1. Absolute neutrophil count \\\u003C1,000 cells\u002Fmm\\^3\n    2. Hemoglobin \\\u003C10 g\u002FdL\n    3. Platelet count \\\u003C100,000 cells\u002Fmm\\^3\n    4. ALT \\>1.5 x ULN\n    5. AST \\>1.5 x ULN\n    6. Total bilirubin \\>1.5 x ULN\n    7. Estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m\\^2\n11. Inability to undergo leukapheresis due to poor venous access or other medical conditions.\n12. Concurrent treatment with any of the medications listed below:\n\n    1. Antiarrhythmics: digoxin\n    2. Anticoagulants: direct oral anticoagulants (DOACs), rivaroxaban, dabigatran, edoxaban\n    3. Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin\n    4. Antiretroviral Agents: atazanavir\u002Fcobicistat, atazanavir\u002Fritonavir, efavirenz, nevirapine, tipranavir\u002Fritonavir\n    5. Antimycobacterials: Rifabutin, rifampin, rifapentine\n    6. Corticosteroids (systemic): dexamethasone, hydrocortisone\u002Fcortisone\n    7. Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine\n    8. Herbal products: St. John's wort c (Hypericum perforatum)\n    9. HMG-CoA reductase inhibitors: lovastatin simvastatin\n    10. Narcotic analgesics metabolized by CYP3A: fentanyl, oxycodone\n    11. Tramadol\n    12. Narcotic analgesic for treatment of opioid dependence: buprenorphine, methadone\n    13. Opioid antagonist: naloxegol\n    14. Phosphodiesterase-5 (PDE-5) inhibitors: sildenafil, tadalafil, vardenafil\n    15. Sedatives\u002FHypnotics: midazolam (oral), triazolam\n13. Past or current medical findings that are not listed above, which, in the opinion of the investigator, may pose additional risk from participation in the study, may interfere with the individual's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.\n\nCo-enrollment guidelines: Co-enrollment in other trials or protocols involving apheresis is restricted, other than enrollment on observational studies. Co-enrollment in an interventional trial will require the approval of the principal investigator. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator.","75 Years",{"count":55,"type":20},50,"INTERVENTIONAL",[58],"PHASE1","Background:\n\nAntiretroviral viral therapy (ART) allows people with human immunodeficiency (HIV) to live long, healthy lives. But ART is not a cure. HIV can remain in the body, in infected cells called reservoirs. If a person stops taking ART, the HIV can rebound and reach high levels in their blood. Researchers want to find ways to reduce the size of HIV reservoirs in people taking ART.\n\nObjective:\n\nTo test a drug (lenacapavir) in people with HIV who are on effective ART. Lenacapavir, also called Sunlenca, is already approved for use in people with HIV who cannot be treated with standard ART.\n\nEligibility:\n\nPeople aged 18 to 75 years with HIV that has been suppressed for at least 3 years with ART.\n\nDesign:\n\nParticipants will have 13 clinic visits over 2 years.\n\nParticipants will be screened. They will have a physical exam with blood tests. They will maintain their ART throughout the study.\n\nParticipants will undergo leukapheresis up to 6 times. Blood will be drawn via a tube in an arm. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be returned to the body through a second tube.\n\nTwo-thirds of participants will take lenacapavir in addition to their regular ART. They will receive the drug as an injection under the skin 3 times at 6-month intervals. They will also take lenacapavir as 2 pills swallowed by mouth on the first 2 days of the study.\n\n...",[24],[62,63,64,65,66],"HIV","ART intensification","Reservoir","lenacapavir","persistence","2026-06-26",{"date":69,"type":38},"2026-06-29",{"date":71,"type":38},"2026-01-20",{"date":73,"type":20},"2029-01-24",{"name":75,"class":45},"National Institute of Allergy and Infectious Diseases (NIAID)",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":21,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100338713","nice-human-immunodeficiency-virus-hiv-cohort-100338713","NCT03690063","Nice Human Immunodeficiency Virus (HIV) Cohort","Inclusion Criteria:\n\n* Enrol consecutive patients with a scheduled visit in the outpatient clinic (regardless of CD4 cell count and ART status).\n\nExclusion Criteria:\n\n\\-",{"count":83,"type":20},2000,"3 Years","Historically, the database on the HIV was organized within the framework of the medico-economic file of the human immunodeficiency (DMI-2), introduced jointly by the Direction of Hospitals (Mission AIDS) and the INSERM at the end of the 80s. Today this database is fed via the computerized medical record NADIS. Most part of the research works on the theme of the HIV take support on this database (DAD, EuroAIDS, Neuradapt).",[24],"2026-06-25",{"date":69,"type":38},{"date":90,"type":38},"1996-01-01",{"date":92,"type":20},"2027-06-25",{"name":94,"class":95},"Centre Hospitalier Universitaire de Nice","OTHER",{"id":97,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":99,"keywords":100,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":106,"locationsCount":46},"100308862",{"count":19,"type":20},[24,25,26,27],[29,27,30,31,32,33],"2026-06-23",{"date":103,"type":38},"2026-06-24",{"date":40,"type":38},{"date":42,"type":20},{"name":44,"class":45},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":56,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100245918","phase-2-cytotoxic-t-lymphocytes-in-treating-patients-with-malignancies-with-bk-andor-jc-virus-100245918","NCT02479698","Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and\u002For JC Virus","Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection","Inclusion Criteria:\n\n* Patients ≥ 2 years. English and non-English speaking patients are eligible.\n* Immunocompromised patients; and\u002For Non-immunocompromised patients with PML\u002FJC virus Encephalitis; and\u002For patients with any type of malignancies; and\u002For HIV\u002FAIDs; and\u002For history of solid organ transplant; and\u002For Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per RECIST criteria.\n* Patients with microscopic hematuria OR biopsy proven BK nephritis and urine or blood PCR positive for BK virus and\u002For JC viral encephalitis and\u002For JC end-organ disease and\u002For polyomavirus.\n* Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg\u002Fkg\u002Fday of prednisone.\n* Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion.\n* Written informed consent and\u002For signed assent from patient, parent or guardian. Patients with cognitive impairments are eligible.\n* Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.\n* Patients enrolled on this study may be enrolled on other IND studies at the discretion of the PI.\n* Patients may be re-enrolled in the protocol should the infection re-occur, provided they meet all the other eligibility criteria at the moment of re-enrollment.\n\nExclusion Criteria:\n\n* Patients receiving prednisone \\> 0.5 mg\u002Fkg\u002Fday at time of enrollment, or have received ATG within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment.\n* Patients with other uncontrolled infections (except HIV\u002FAIDS). For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection\n* Patients with active acute (GVHD) grades II-IV",{"count":115,"type":20},100,[117],"PHASE2","This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and\u002For JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and\u002For JC virus.",[120,121,24,122,123,124,125,126],"Acquired Immunodeficiency Syndrome","BK Virus Infection","JC Virus Infection","Malignant Neoplasm","Merkel Cell Carcinoma","Merkel Cell Polyomavirus Infection","Viral Encephalitis","2026-06-10",{"date":129,"type":38},"2026-06-12",{"date":131,"type":38},"2015-07-23",{"date":133,"type":20},"2027-07-31",{"name":135,"class":95},"M.D. Anderson Cancer Center",{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":143,"sex":16,"minAge":144,"maxAge":53,"enrollmentInfo":145,"targetDuration":4,"studyType":56,"phases":147,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":46},"100526782","gut-microbiota-mediated-inflammatory-interactions-between-aud-and-hiv-infection-100526782","NCT06139224","Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection","Gut Microbiota-Mediated Inflammatory Interactions Between Alcohol Use Disorders and HIV Infection","Inclusion Criteria:\n\n* Age 21 to 75 years men and women\n* Infection with HIV-1, as documented by a licensed ELISA and confirmed by a Western blot or HIV-1 RNA\n* On ART for at least 12 months. No history of zidovudine (AZT) or stavudine (D4T) use.\n* No change in ART for at least 6 months.\n* CD4+ T cell count of \\> 250 cells\u002Fµl, nadir CD4+ T cell count of \\> 250 cells\u002Fµl\n* Plasma HIV-1 RNA level consistently below the limit of detection of commercial ultrasensitive assay (usually \\\u003C20 copies\u002FmL) for at least six months before study entry.\n* For those for \"AUD group\" AUDIT-C =\u002F\\> 4 for men and = ≥3 for women.\n* Documented BMI between 25-40\n* Ability and willingness to provide informed consent\n\nExclusion criteria:\n\n* Receipt of a non-HIV vaccine within 30 days\n* Opportunistic infection within 30 days\n* Immunosuppressive medications (e.g., systemic corticosteroids, tacrolimus, sirolimus, mycophenolate, azathioprine, interferon, and cancer chemotherapy) within 90 days\n* History of clinically significant medical disease that could potentially impact the integrity of intestinal barrier function or microbiota including renal (creatinine \\>2 mg\u002FdL), liver (documented cirrhosis based on histology or ALT\u002FAST greater than 2 1\u002F2 times normal), cardiac failure (NY classification III\u002FIV), or uncontrolled diabetes (Hgb-A1c\\>8%).\n* Fiber intake \\> 15 grams.\n* Chronic HBV and un-treated HCV (documentation of cure can be enrolled)\n* Herbal\u002Fbotanical supplements with potential microbiome or anti-inflammatory effects (e.g., inulin\u002Fchicory fiber, berberine, high-dose polyphenols). Participants will be eligible to participant if they discontinue use for at least 2 weeks before enrollment.\n* Regular use of medications that affect intestinal permeability including NSAIDs (daily more than three days a week during the prior two weeks). Type and frequency and duration of NSAID (those taking less than 3 \u002Fper week) should be recorded. If participants need to take antibiotics or NSAIDS during the study, duration, name, and dosage will be recorded but they will not be excluded.\n* Antibiotics (during or prior) four weeks to enrollment. Type and duration of antibiotic treatment within 90 days should be recorded.\n* Current use of a restrictive or specialty diet like vegan, vegetarian, gluten-free, Paleo, or any specific carbohydrate diet because these diets can impact the microbiota community.\n* Use of herbal, botanical, or nutraceutical supplements with potential effects on the gut microbiome or systemic inflammation. This includes:\n\nprebiotic fibers such as inulin, chicory root, fructooligosaccharides (FOS), or galactooligosaccharides (GOS) botanical or herbal compounds with microbiome-modulating or anti-inflammatory properties, such as berberine, curcumin, resveratrol, or high-dose polyphenol Probiotics or synbiotics Digestive enzymes or other nutraceuticals reported to alter gut microbial composition.\n\nPotential participants may enroll if they discontinue use for at least 2 weeks before enrollment. Type, dosage, frequency, route of administration (for example oral), and date last taken will be documented at time of enrollment verify that a sufficient washout period has occurred before enrollment.\n\n-Have undergone bowel preparation or colonic (e.g., for a colonoscopy or similar procedure) for example, within 4 weeks prior to enrollment.\n\nInflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease). Celiac disease. GI cancers\n\n* Gastrointestinal surgeries\u002Fresection (cholecystectomy is accepted but should be recorded)\n* Currently taking or planning to start a GLP-1 receptor agonist or dual GLP-1\u002FGIP receptor agonist for weight loss or weight management. This includes medications such as semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), lixisenatide (Adlyxin), and tirzepatide (Mounjaro, Zepbound). Participants who previously used these medications may be eligible if they discontinued use at least 4 weeks prior to enrollment. For eligible individuals, the medication name, dosage, frequency, route of administration (for example injection or oral), and date of last dose will be documented at enrollment. The study team will document the last dose to verify that a sufficient wash out period has occurred before enrollment and to account for any possible microbiome differences.\n* Use of PPI is accepted but type, dose and duration should be recorded.",true,"45 Years",{"count":146,"type":20},40,[148],"NA","Alcohol use disorder (AUD) has been associated with high prevalence of inflammation-associated co-morbidities in people living with HIV even those receiving effective antiretroviral therapy (ART). Our preliminary data support a model in which the combined insult of AUD and HIV on the gut, specifically on the microbiota and intestinal barrier integrity, exacerbates inflammation. Our preliminary data using intestinal organoids also suggest a potential mechanism for AUD-mediated changes in the gut barrier function during HIV; the intestines of HIV+ individuals have low resilience to alcohol induced intestinal barrier disruption caused by high levels of oxidative stress. Finally, our preliminary data also suggest a potential approach to enhance the integrity of the intestinal barrier and reduce gut derived inflammation in people living with HIV with\u002Fwithout AUD- short chain fatty acid prebiotics. These prebiotics prevent alcohol mediated adverse effects on the intestinal barrier and inflammation by preventing oxidative stress. These prebiotics are safe and decrease gut inflammation in humans.\n\n40 HIV+ ART+ (20 AUD- and 20 AUD +), will be recruited for a prebiotic intervention. This is a proof-of-concept intervention study to establish a causal link between microbiota-gut and HIV pathology during ART by asking whether modifying microbiota and gut milieu impacts intestinal barrier function, systemic inflammation, and brain pathology in HIV+ people. Participants will complete three in-person clinic visits and four virtual check-in visits during this 8 week study. This study uses a crossover design. At baseline, participants will be randomized to receive either a prebiotic or a placebo for the first intervention period. After completing this period, participants will cross over to receive the alternate study product for the second intervention period, allowing each participant to serve as their own control. These participants are part of the larger observation study (n=160), which will test the hypothesis that intestines from HIV+ individuals have lower resilience to alcohol mediated gut barrier disruption than intestines from HIV-negative controls. New participants will also be recruited. Blood, urine, and stool, will be collected from participants to compare intestinal barrier integrity, system and gut inflammation, immune activation, oxidative stress, microbiome\u002Fmetabolome. and HIV reservois.",[151,24],"Alcohol Use Disorder","2026-06-02",{"date":154,"type":38},"2026-06-04",{"date":156,"type":38},"2024-03-05",{"date":158,"type":20},"2029-08-31",{"name":160,"class":95},"Rush University Medical Center",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":56,"phases":171,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":46},"100534015","phase-1-use-of-acu-d1-in-hpv-associated-vulvar-and-perianal-lesions-in-people-with-hiv-100534015","NCT06233331","Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV","Phase I Dose Escalation Study of the Use of ACU-D1, a Topical Proteasome Inhibitor in HPV Associated Vulvar and Perianal Lesions in People With HIV","Inclusion Criteria:\n\n* Age 21 years and older\n* HIV-infected\n* Able to provide informed consent\n* Biopsy-proven HSIL disease of the vulvar and perianal region with a total disease volume of 3 cm or greater\n* Combined antiretrovirals (cART) adherence\n* CD4 count \\> 200 cells\u002Fml\n* Sustained undetectable viral load for ≥ 3 months\n* If applicable, on reliable birth control such as combined oral contraceptive pills (OCP), bilateral tubal ligation (BTL), a long-acting reversible contraceptive, or Depo-Provera (birth control shot)\n* Willingness to conform to study requirements\n* Reliable follow-up and contact information\n* No risk factors or clinical suspicion for micro-invasive disease and absence of medical condition that interferes with the conduct of the study in the investigator's opinion\n\nExclusion Criteria:\n\n* Currently pregnant (confirmed by collecting urine for HCG pregnancy test) or lactating","21 Years",{"count":170,"type":20},9,[58],"The goal of this study is to test the maximum tolerated dose of ACU-D1 in HIV-positive people with HPV-associated vulvar and perianal lesions. The main questions it aims to answer are:\n\n* The maximum tolerated dose of ACU-D1\n* Safety and tolerability of topical ACU-D1\n* Whether topical ACU-D1 induces p53 and p53-mediated downstream signaling (including p21 induction) in HPV-related lesions\n* Whether topical ACU-D1 enhances markers of immunity in HPV-infected HIV-positive individuals\n\nParticipants will be asked\n\n* To apply ACU-D1 on the lesions twice daily for 4 weeks\n* 3 biopsies will be performed at the screening and 3 at the end of 4 weeks.",[174,24,175,176],"Human Papilloma Virus","Anal Intraepithelial Neoplasia","High-Grade Squamous Intraepithelial Lesions",[62,178,175],"HPV","NOT_YET_RECRUITING","2026-05-05",{"date":182,"type":38},"2026-05-08",{"date":184,"type":20},"2026-06",{"date":186,"type":20},"2027-12",{"name":188,"class":95},"Emory University",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":196,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":56,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100525086","integrated-mental-health-care-for-pregnant-women-with-hiv-in-kenya-the-tunawiri-study-100525086","NCT06117163","Integrated Mental Health Care for Pregnant Women With HIV in Kenya: The Tunawiri Study","Integration of a Collaborative Care Model for Mental Health Services Into HIV Care for Pregnant and Postpartum Women in Kenya (the Tunawiri Study)","Inclusion Criteria:\n\n* pregnant woman living with HIV attending an antenatal clinic in southwestern Kenya\n* screening positive for probable common mental disorders\n* living in catchment area of study facility.\n* on\u002Finitiating ART\n* \\>15 years of age\n\nExclusion Criteria:\n\n* imminent plans of suicide\n* severe impairment due to severe mental, neurological or substance use disorders.","FEMALE","15 Years",{"count":199,"type":20},900,[148],"This study seeks to improve mental health, pregnancy, and HIV outcomes among pregnant and postpartum women living with HIV with common mental health disorders in Kenya. The investigators will tailor a collaborative care model for peripartum women with HIV experiencing mental health symptoms and evaluate its impact on participants' mental health, antenatal, and HIV care outcomes. The investigators will actively engage key stakeholders throughout the process and assess scalability and sustainability through multi-method approaches. This study will contribute to the overall goal of achieving optimal health outcomes for women living with HIV and their families in sub-Saharan Africa.",[24,203],"Mental Disorder",[205,206,207,208,209,210,211,212,213,214,215,216,217,218],"HIV transmission","Prevention of Mother to Child Transmission","Linkage to care","Retention in care","Antiretroviral therapy adherence","Infant Health","Maternal CD4\u002Fviral loads","Early infant diagnosis","Acceptability of interventions","Vertical transmission","Mental Health","The Collaborative Care Model","Problem Solving Therapy","Stigma","2026-05-04",{"date":221,"type":38},"2026-05-06",{"date":223,"type":38},"2024-10-01",{"date":225,"type":20},"2028-05-31",{"name":227,"class":95},"University of Colorado, Denver",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":143,"sex":235,"minAge":17,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":56,"phases":238,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":46},"100526279","medical-mistrust-among-hispaniclatino-gay-bisexual-and-other-men-who-have-sex-with-men-hlmsm-100526279","NCT06132672","Medical Mistrust Among Hispanic\u002FLatino Gay, Bisexual and Other Men Who Have Sex With Men (HLMSM)","Identifying and Addressing Historical and Structural Drivers of Medical Mistrust Among Hispanic\u002FLatino Gay, Bisexual and Other Men Who Have Sex With Men","Inclusion Criteria:\n\n* reside in Mecklenburg County, NC\n* identify as Hispanic\u002FLatino\n* be ≥18 years of age\n* speak English and Spanish\n* report identifying as male and having had sex with at least 1 man in the past 6 months\n* provide informed consent\n\nExclusion Criteria:\n\n* less than 18 years of age\n* female","MALE",{"count":237,"type":20},144,[148],"There is an urgent need to address HIV inequities and disparities in the US, particularly within vulnerable communities such as Hispanic\u002FLatino gay, bisexual, and other men who have sex with men (HLMSM).",[24],[242,243,244],"Hispanic\u002FLatino gay","bisexual men","HIV prevention","2026-04-27",{"date":247,"type":38},"2026-04-30",{"date":249,"type":20},"2027-03",{"date":251,"type":20},"2028-08",{"name":253,"class":95},"Wake Forest University Health Sciences",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":56,"phases":263,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":46},"100436045","phase-3-cefixime-clinical-trial-100436045","NCT04958122","Cefixime Clinical Trial","Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis","Inclusion Criteria:\n\n* Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment\n* 18 years of age or older\n* Able to provide informed consent\n* Individuals with HIV infection must be on treatment for HIV infection and virologically suppressed (viral load \\\u003C200 copies\u002FmL) or have a CD4 count ≥ 350 cells\u002Fmm3 according to most recent labs before study enrollment\n\nExclusion Criteria:\n\n* Pregnancy or a positive pregnancy test on the day of enrollment\n* Patients showing signs and symptoms of neurosyphilis\n* Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater\n* Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, doxycycline, ceftriaxone, or other beta-lactam antibiotics (e.g. amoxicillin)\n* Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test\n* Self-reported allergy to cephalosporins or penicillin\n* Unwilling or unable to attend follow-up visits",{"count":262,"type":20},400,[264],"PHASE3","This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.",[267,24],"Syphilis",[269,270,271,272],"Cefixime","Treponema pallidum","Penicillin","Early Syphilis",{"date":219,"type":38},{"date":275,"type":38},"2021-06-20",{"date":277,"type":20},"2027-06-30",{"name":279,"class":95},"University of Southern California",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":143,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":289,"conditions":290,"keywords":293,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":302,"locationsCount":304},"100470353","harm-reduction-in-hiv-primary-care-for-plwh-who-use-drugs-100470353","NCT05404750","Harm Reduction in HIV Primary Care for PLWH Who Use Drugs","Impact of Harm Reduction Care in HIV Clinical Settings on Stigma and Health Outcomes","Inclusion Criteria:\n\n1. Providers' Inclusion Criteria\n\n   * Working at one of our 3 study sites (UPMC HIV\u002FAIDS Program, Positive Health Clinic, or 1917 Clinic) or one of their partner sites offering substance use treatment (Internal Medicine Recovery Engagement Program, Center for Inclusion Health, or UAB's Outpatient-Based Opioid Treatment Clinic) for at least one year\n   * Providing service or care to PLWH or people who use drugs at high risk for HIV acquisition\n   * Working in one of the following positions: front desk\u002Fpatient engagement, social worker, nurse, medical assistant, advanced practice provider, or physician\n   * Able to verbally consent, read, and speak English\n2. Patient Inclusion Criteria\n\n   * Living with HIV\n   * Age 18 or older\n   * Able to verbally consent, read, and speak English\n   * Receiving HIV medical care from one of the study sites for at least one year\n   * Lifetime or recent use (past 3 months) of illicit substances (excluding marijuana) or prescription drugs for non-medical reasons in accordance with the NIDA-Modified ASSIST 2.0.\n\nExclusion Criteria:\n\n\\-",{"count":288,"type":20},768,"People living with HIV (PLWH) who use drugs experience significant health disparities including lower rates of retention in HIV care and higher rates of unsuppressed viral load, resulting in secondary infections and increased mortality. The proposed study will used mixed methods to explore (a) the relationship between healthcare providers' attitudes towards working with PLWH who use drugs and providers' acceptance and practice of structural and relational harm reduction; (b) the degree to which relational harm reduction moderates the effect of intersectional stigma experienced in healthcare settings on patients' perceptions of their relationship with providers; (c) the degree to which structural HR moderates the relationship between the patient-provider relationship and clinical outcomes, and (d) whether patient-perceived HR approaches to care are directly associated with HIV clinical outcomes. The study will also use these findings to inform the development and pre-testing of an intervention to operationalize harm reduction in HIV clinical settings, using stakeholder-engaged and human-centered design approaches, presenting a novel path to reducing HIV health inequities for PLWH who use drugs.",[24,291,292],"Substance Use","Stigma, Social",[294,295],"Harm Reduction","Patient-Provider Relationship","2026-04-21",{"date":298,"type":38},"2026-04-24",{"date":300,"type":38},"2022-04-20",{"date":277,"type":20},{"name":303,"class":95},"University of Pittsburgh",3,{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":56,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":329,"locationsCount":46},"100633708","phase-1-hiv-therapeutic-dna-vaccine-icvax-phase-i-clinical-trial-in-hong-kong-100633708","NCT07530198","HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong","HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong: Evaluation of Immunogenicity and Safety of ICVAX in ART-treated Clinically Stable HIV-infected Patients","Inclusion Criteria:\n\n1. Tested positive for HIV-1 antibody;\n2. Aged 18-60, both male and female;\n3. BMI (body mass index) in between 18.5 and 24.9 kg\u002Fm2 (including upper and lower limits);\n4. Received ART for ≥12 months; no drug resistance occurred during this treatment period;\n5. Had \\\u003C50 copies\u002Fml of plasma HIV RNA for at least (≥) 12 months prior to screening visit;\n6. Had ≥350 cells\u002FμL of CD4+ T cells in the past 6 months and \\>200 cells\u002FμL of CD4+ T cells before initiation of ART;\n7. Adopted contraception method approved by the investigator from screening period until the end of study;\n8. Understand the study and voluntarily sign the ICF.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding or those who plan to give birth in coming two years (including the subject and his\u002Fher spouse);\n2. ART has been suspended for more than 2 weeks continuously since ART initiation;\n3. Participated in other clinical trials within 24 weeks before the screening visit;\n4. Has any opportunistic infections or opportunistic tumors that require systemic treatment within 30 days before being recruited; Has any medical events that the investigator believes will affect the safety and immunogenicity evaluation of the drug;\n5. Has a history of autoimmune diseases; Has hypersensitivity to the components of this drug including ICVAX recombinant plasmid, NaCl, Na2HPO4 and NaH2PO4·H2O, and shows severe allergies, such as dyspnea, edema and other symptoms after administration;\n6. Received approved vaccines within the past 3 months;\n7. Received any blood products, immunoglobulin products, or immunosuppressants within 12 weeks before being recruited;\n8. Used interferon, systemic corticosteroids, or other immunosuppressants within the last 3 months (except local application);\n9. Positive Hepatitis B surface antigen (HBsAg) within 12 months, or positive Hepatitis C virus antibody (HCV Ab) at screening with confirmatory HCV RNA positive;\n10. Has any abnormal laboratory results including: neutrophil \\\u003C1×109\u002FL, serum creatinine \\> ULN, ALT or AST \\>1.5×ULN, hemoglobin \\\u003C 11g\u002FdL;\n11. Has any medical history or clinical manifestations of any physical or mental illness that may affect the subject's completion of this study;\n12. Sensitive to electrical pulse stimulation, such as those who are implanted with pacemaker\u002F Automatic Implantable Cardioverter Defibrillator (AICD), or those who have wearable medical electronic devices including electrocardiogram;\n13. Needle phobia;\n14. Have contraindications for intramuscular administration such as confirmed thrombocytopenia, any coagulation dysfunction or currently receiving anticoagulation therapy;\n15. The investigator considers that he\u002Fshe is not suitable to participate in this trial.","60 Years",{"count":314,"type":20},22,[58],"The goal of this randomized clinical trial is to evaluate the safety and immunogenicity of the HIV Therapeutic DNA Vaccine (ICVAX) in participants with HIV-1 infection under antiretroviral therapy (ART). The study compares three delivery methods - Teresa -EPT I, PharmaJet Tropis, and PapiVax TriGrid EP - to induce antigen-specific T cell responses in the participants.\n\nThe primary objectives are to evaluate the safety of ICVAX delivered using three different devices in the participants within the period Day 0-Day 336, and to evaluate the antigen-specific T cell responses induced by ICVAX in the participants within the period Day 0-Day 168.\n\nThe participants will receive four injections of ICVAX administered at 4-week intervals. Following the final dose, participants will be monitored for 36 weeks.",[24,318],"Human Immunodeficiency Virus I Infection",[320,62,321,322],"ICVAX","AIDS","DNA Vaccine","2026-04-08",{"date":325,"type":38},"2026-04-15",{"date":327,"type":38},"2026-03-30",{"date":133,"type":20},{"name":330,"class":331},"Immuno Cure Holding (HK) Limited","INDUSTRY",{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":339,"targetDuration":4,"studyType":56,"phases":341,"briefSummary":343,"conditions":344,"keywords":346,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":356,"locationsCount":304},"100480588","phase-4-low-dose-naltrexone-for-pain-in-patients-with-hiv-100480588","NCT05537935","Low Dose Naltrexone for Pain in Patients With HIV","Low Dose Naltrexone (LDN) for the Treatment of Chronic Neuropathic Pain in Patients With Human Immunodeficiency Virus (HIV), a Prospective, Pragmatic, Open Label Clinical Trial","Inclusion Criteria:\n\n* Age 18-75, male and female\n* HIV infection with a viral load of \\\u003C 1000 copies\u002Fml for the past 12 months. (That is the viral load below which, according to the 2018 American College of Obstetricians and Gynecologists (ACOG) Committee Opinion, there is no thought of a significant risk of HIV transmission from the mother to the fetus with vaginal delivery. This was thought to be a reasonable cut-off for inclusion in this study.)\n* Diagnosis of neuropathic pain (pain that is associated with a lesion or disease involving the somatosensory nervous system, e.g., painful neuropathy, radicular pain, complex regional pain syndrome, nerve-related pain following spine surgery, etc.) using the neuropathic pain screening tool, painDETECT17, as part of the neuropathic pain screen.\n* Pain score \\> 4\u002F10 on average on the NPRS lasting \\> 3 months (chronic pain)\n* Capable of informed consent and willing to comply with the study requirements\n* Fluent English-speaking\n\nExclusion Criteria:\n\n* Allergy to naltrexone (not applicable to the control group)\n* Current use of any opioids, up to 10 days before the start of the study (not applicable to the control group)\n* Pregnant women\n* Nursing mothers and women of childbearing potential not using contraception known to be highly effective (not applicable for the control group). Highly effective contraception methods include a combination of any two of the following during the 12-week study period:\n\n  1. Use of oral, injected, or implanted hormonal methods of contraception or;\n  2. Placement of an intrauterine device (IUD) or intrauterine system (IUS);\n  3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical \u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository;\n  4. Total abstinence;\n  5. Male\u002Ffemale sterilization.\n* Bipolar disorder, schizophrenia, poorly controlled anxiety or depression\n* Diagnosis of liver disease, e.g. cirrhosis\n* Current diagnosis of either chronic kidney disease or acute kidney injury and\u002For a GFR \\\u003C45 at baseline\n* Acute viral hepatitis A, B, C\n* Patients who self-report as having tested positive for COVID-19 or have been diagnosed with another viral illness within the past ten days.\n* Patients with a known or suspected diagnosis of long-term COVID\n* Active drug or alcohol use disorder\n* People who may require opioid therapy during the duration of the study, e.g. upcoming surgery\n* Transportation issues interfering with return study visits (NA for the control group)\n* Adults unable to consent\n* Prisoners",{"count":340,"type":20},60,[342],"PHASE4","The increased life expectancy of Patients Living With HIV\u002FAIDS (PLWHA) has increased the need for therapies for chronic conditions, such as chronic pain. Pain in the HIV population is often refractory and ends up being treated with chronic opioids, which are associated with adverse effects, including hyperalgesia, constipation, and risk of overdose. Naltrexone is an opioid antagonist used in the treatment of alcohol and opioid use disorders. Low Dose Naltrexone (LDN), naltrexone at a much lower dose, is thought to be an immune modulator and has been associated with an increased CD4 count in PLWHA. Repurposing this medication is relatively inexpensive and has the potential to expand access to treatment for a painful condition experienced in PLWHA. While there are many case reports on the efficacy of LDN in symptom reduction, there are only a small number of clinical trials that specifically examine pain and symptom relief.\n\nThis study will include patients who are not completely virologically controlled and will monitor the CD4 counts drawn as a part of routine care. If the CD4 count improves with LDN and with reduced symptoms, this could be a significant improvement in HIV therapy for symptom control. There have been studies showing cytokine reduction in fibromyalgia patients but they did not investigate the correlation with cytokines and pain relief. This study involves repurposing a drug used for substance use disorder to a medication with the potential to treat pain and improve symptoms for PLWHA.",[24,345],"Chronic Neuropathic Pain",[347,348,349],"Low dose Naltrexone","Naltrexone","Pain","2026-04-06",{"date":352,"type":38},"2026-04-09",{"date":354,"type":38},"2023-04-28",{"date":277,"type":20},{"name":188,"class":95},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":56,"phases":367,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":383},"100474028","phase-2-baricitinib-for-reduction-of-hiv---cns-100474028","NCT05452564","Baricitinib for Reduction of HIV - CNS","Phase II Study to Evaluate the Efficacy and Safety of Baricitinib for Reduction of HIV in the Central Nervous System","Inclusion Criteria:\n\n1. HIV infected on continuous ART with plasma HIV RNA \\\u003C200 copies\u002Fml for at least 12 months (on at least two previous clinic visits and confirmed at screening). If a viral load is documented from a CLIA-certified laboratory 14 days before screening, then this result can be used in place of the screening lab result.\n2. Current CD4+ \\> 350 cells\u002Fmicroliter for at least twelve months (on at least two previous clinic visits and confirmed at screening). If a CD4 count is documented from a CLIA-certified laboratory 30 days before screening, then this result can be used in place of the screening lab result.\n3. Women of reproductive age will have a negative pregnancy test at study entry and agree to contraception while on the study drug. Women who are at least 50 years of age and who have been amenorrheic for at least 12 months will not be required to agree to contraception to participate.\n\nExclusion Criteria:\n\n1. \\\u003C 18 years of age or \\> 65 years of age\n2. Pregnancy or breastfeeding\n3. Significant hematological abnormalities at screening (ANC \\\u003C 1000, Hgb\\\u003C10, platelet\\\u003C 100,000)\n4. History of progressive multifocal leukoencephalopathy\n5. Untreated latent tuberculosis infection (which will be screened for before entry). If there is a prior positive test, the test does not need to be repeated at screening.\n6. Immunosuppressive medications (including corticosteroids) and anticoagulants (aspirin acceptable) within 1 month. A partial list is provided in the SOP for staff, but otherwise, if there is a question it will be adjudicated by the Investigator(s).\n7. History of deep venous thrombosis\n8. Cardiovascular disease:\n\n   1. Coronary artery disease or history of myocardial infarction, no exclusion if greater than 3 months\n   2. Congestive heart failure with left ventricular ejection fraction ≤40% per American Heart Association guidelines-- no exclusion if greater than 3 months\n   3. Ever a history of stroke\n9. Hematologic malignancies including lymphoma and leukemia which have no evidence of cure or are at least in remission for \\> 5 years\n10. Major surgery within 8 weeks before screening or will require major surgery during the study\n11. Current or recent (\\\u003C4 weeks before randomization) clinically serious viral (including COVID-19), a bacterial, fungal, or parasitic infection or any other active or recent infection. History of untreated syphilis infection. If an RPR was negative in the 3 months before screening, then an RPR is not needed at screening\n12. Symptomatic herpes simplex at the time of randomization\n13. Symptomatic herpes zoster infection within 12 weeks before randomization.\n14. History of disseminated\u002Fcomplicated herpes zoster (for example, ophthalmic zoster or CNS involvement).\n15. Positive test for hepatitis B virus (HBV) defined as:\n\n    1. positive for hepatitis B surface antigen (HBsAg), or\n    2. positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA)\n16. Hepatitis C virus (HCV) chronic infection (hepatitis C antibody-positive and HCV ribonucleic acid \\[RNA\\]-positive), ever.\n17. Cirrhosis of the liver from any cause\n18. Any of the following specific abnormalities on screening laboratory tests:\n\n    1. ALT or AST \\>2 x upper limits of normal (ULN)\n    2. alkaline phosphatase (ALP) ≥2 x ULN\n    3. total bilirubin ≥1.5 x ULN (except patients on atazanavir, who must have total bilirubin \\\u003C2 x ULN)\n    4. International Normalized Ratio (INR) \\> 1.5\n    5. Absolute Neutrophil Count (ANC) \\\u003C1000 cells\u002Fmm3, confirmed on repeat testing.\n19. Chronic kidney disease with eGFR \\\u003C40 mL\u002Fmin\u002F1.73 m2 (note that the dose of baricitinib will be reduced to 1 mg daily in participants with GFR between 40 and 60). Specifically, the CKD-EPI without race-based equation is used\n20. Current dependence on illicit drugs except for marijuana\n21. Bleeding disorders such as Von Willebrand's Disease, hemophilia, or other coagulopathies as determined by history.\n22. Any evidence of a mass lesion by history that could lead to increased intracranial pressure and evidence of trauma to the lumbar vertebra (see LP exclusion criteria above) by history. - no lumbar trauma or surgery in the last 60 days, but this will be adjudicated by Investigator(s) if need be.\n23. Population: The study team will not include any of the following groups:\n\n    * Adults unable to consent\n    * Individuals who are not yet adults (infants, children, teenagers)\n    * Pregnant women\n    * Prisoners\n    * Cognitively impaired or Individuals with Impaired Decision-Making Capacity\n    * Individuals who are not able to clearly understand English\n    * Community Participation (if applicable)","65 Years",{"count":366,"type":20},95,[117],"There is still no cure for the human immunodeficiency virus (HIV). While combination antiretroviral therapy (cART) is effective in decreasing deaths from HIV, infected individuals face a lifetime of treatment and many potential complications including end organ diseases such as HIV-associated neurocognitive disorders. HIV infection is controllable with antiretroviral therapy (ART), but ART cannot eliminate HIV reservoirs. Thus, there is no available cure for HIV. There is a large and growing body of evidence that the central nervous system (CNS) is an HIV reservoir site and a barrier to HIV eradication. Our group has done extensive pre-clinical work with janus-kinase (JAK 1\u002F2) inhibitors. This includes baricitinib, which is an orally available, FDA-approved drug for rheumatoid arthritis. Evidence suggests that this drug has activity against HIV in the central nervous system (CNS). In our recently completed pilot study, we showed that baricitinib crosses the blood brain barrier (BBB) and decreases HIV CNS persistence in the brain.\n\nUsing bloodwork, neurocognitive testing, MRIs and lumbar punctures, we plan to evaluate the change in central nervous system HIV after treatment with baricitinib versus placebo. We will also evaluate changes in neuroimaging, inflammation in blood and cerebrospinal fluid (CSF), and neuropsychological performance after treatment with baricitinib versus placebo.\n\nEvidence shows that the central nervous system is one of the reservoir sites that enables the HIV virus to persist in the body even after years of treatment. In order to attack this reservoir and eventually find a cure, it is vital to learn if certain medications can suppress HIV in the CNS.",[24],[371,372,373],"Central Nervous System","Cerebrospinal Fluid","Baricitinib","2026-03-19",{"date":376,"type":38},"2026-03-23",{"date":378,"type":38},"2023-05-18",{"date":380,"type":20},"2028-01",{"name":382,"class":95},"William Tyor",2,{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":143,"sex":196,"minAge":17,"maxAge":144,"enrollmentInfo":391,"targetDuration":4,"studyType":56,"phases":393,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":404,"locationsCount":406},"100477356","phase-4-a-study-of-reduced-dosing-of-the-nonavalent-hpv-vaccine-in-women-living-with-hiv-100477356","NCT05495906","A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV","NOVA-HIV","Inclusion Criteria:\n\n* Living with HIV\n* Has a uterine cervix\n\nExclusion Criteria:\n\n* Unable to give fully informed consent\n* Pregnant or unwilling to avoid pregnancy during vaccination\n* Allergy to the vaccine or its components\n* Prior receipt of any HPV vaccine",{"count":392,"type":20},275,[342],"There are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer. Particularly, there are no data to date on reduced-dose schedules of nonavalent HPV (9vHPV) vaccination in WLWH and there are very little data on the 9vHPV vaccine in this population overall. It is critical to examine the 9vHPV vaccine in WLWH now because the quadrivalent HPV (4vHPV) vaccine has been discontinued. Additionally, in order to reach the World Health Organization's global goal of cervical cancer elimination, we must determine the role of various HPV prevention strategies in this important population including reduced vaccine dosing which can drastically increase the feasibility of HPV vaccination programs globally.\n\nThis randomized clinical trial will enrol WLWH aged 18-45 from across Canada who have not previously received an HPV vaccine. Participants will be randomized 1:1 to receive 3 doses of 9vHPV vaccine at the routine vaccine schedule of 0\u002F2\u002F6 months or 2 doses at an expanded schedule of 0\u002F6 months with a third dose at month 12 to adhere to current recommendations for WLWH. We will compare the immune response generated to two versus three doses of 9vHPV vaccine and will follow participants for 2 years to examine the immune response over time.\n\nThis study, which builds upon our team's prior work on HPV vaccination in WLWH, will determine whether two doses of 9vHPV vaccine can be used in WLWH instead of three, and will examine additional aspects of HPV vaccination in WLWH including the immune response to three doses, vaccine safety and efficacy, and attitudes towards self-collected HPV samples in this population. These data will inform global public health policy and programming and will inform the global strategy for cervical cancer elimination.",[178,174,24],[397],"HPV vaccination","2026-02-03",{"date":400,"type":38},"2026-02-05",{"date":402,"type":38},"2023-07-27",{"date":380,"type":20},{"name":405,"class":95},"University of British Columbia",10,{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":143,"sex":16,"minAge":415,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":46},"100547451","universal-test-and-connect-for-hiv-service-delivery-in-south-africa-100547451","NCT06408142","Universal Test and Connect for HIV Service Delivery in South Africa","Universal Test and Connect for HIV Service Delivery in South Africa and Baltimore","UTC: SA","Inclusion Criteria for universal testing and connecting:\n\n* Patients attending the Emergency Department\n* Ages \\> or = 12 years old in South Africa\n* For subset that participate in PrEP choice trial, inclusion criteria will be to ensure that they meet PrEP eligibility criteria and do not have any contraindications to PrEP (kidney disease, acute HIV signs or symptoms, already taking PrEP).\n\nExclusion Criteria:\n\n* Patients unable to provide written informed consent - i.e., have a depressed level of consciousness (head trauma or concurrent alcohol\u002Fsubstance abuse), determined as critically ill (triage score of \"emergent\"), or\n* do not speak a language spoken by the study team (English, Afrikaans, and Xhosa).\n\nIn-depth interviews and surveys to providers:\n\nInclusion Criteria:\n\n* Nurses, physicians, or advanced practice providers (APPs) who work regularly in the Emergency Department at one of the clinical sites.\n* Consent to a recorded in-depth interview and\u002For Normalizing Process Theory (NPT) survey\n\nExclusion Criteria:\n\n* Providers who have already been interviewed (if working at both clinical sites)\n* Providers who do not consent to an interview or a survey.","12 Years",{"count":83,"type":20},"The goal of this study is to determine how many patients with HIV or at high risk of getting HIV attend the Emergency Department (ED) in South Africa (SA). The investigators will integrate HIV assessment in the ED and see how many people who would be a candidate for a drug that prevents HIV (PrEP). Universal test and connect (UTC) is a strategy that universally tests all patients and connects patients to long-term care, whether HIV positive or negative, including referrals for PrEP. The investigator's goal is to use UTC across two busy 24-hr EDs in Cape Town, SA.",[24,419,420,421],"Pre-Exposure Prophylaxis","Emergency Department","South Africa","2026-01-28",{"date":424,"type":38},"2026-01-30",{"date":426,"type":38},"2026-01-19",{"date":428,"type":20},"2027-12-01",{"name":430,"class":95},"Johns Hopkins University",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":56,"phases":439,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":46},"100558676","the-sustain-2-study---sustained-hiv-treatment-for-adherence-after-interruption-in-care-100558676","NCT06554223","The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care","Inclusion Criteria:\n\n* Adults (≥18 years or age)\n* Living with HIV\n* On a dolutegravir-based first-line ART regimen\n* Evidence of a care gap (\\>28 days late for appointment) or having a raised viral load (≥50 copies\u002Fml) in the preceding year, either from SUSTAIN study data or from clinic records.\n* Able to provide full informed consent.\n* Willingness to comply with study procedures, including providing regular update of contact details or locator information.\n\nA purposively selected subset of 30 enrolled participants will be invited for a semi-structured, in-depth interview at (or within 2 months after) the month 24 visit (for experience and perceptions; aim 2); and 20 different participants will be invited to participate in in-depth interviews to determine acceptability and feasibility (aim 3) within the same time frame.\n\nExclusion Criteria at Enrollment:\n\n* Clinical conditions as assessed by the ART clinicians as requiring clinic-based follow-up e.g. tuberculosis or epilepsy.\n* Pregnant at enrollment and requiring care in the antenatal clinic system.\n* Sustained retention in care (no gaps of \\>28days) and viral suppression in the preceding year.\n* Plans to leave Cape Town permanently within the next 24 months.",{"count":438,"type":20},310,[148],"The goal of this clinical trial is to learn if the DSD model (SUSTAIN-DSD) is effective in improving participants HIV treatment adherence. The main questions it aims to answer are:\n\n* Does the SUSTAIN-DSD intervention significantly improve participants' treatment adherence and increase rates of viral suppression?\n* Does the SUSTAIN-DSD intervention help retain people in care?\n* Does SUSTAIN-DSD intervention help reduce the length of treatment interruptions?\n* for 24 months, Participants will either receive the SUSTAIN-DSD intervention (i.e. be enrolled in an adherence club where the participants will pick up 6-months of ART medication and have the option to use peer support and additional counseling), and or enhanced standard of care (i.e. visit the clinic for treatment and participate in optional counseling sessions).\n\nBlood will be drawn from the participants at the adherence club visits for viral load tests at baseline and every 12 months.\n\n\\- Participants will take part in interviews to discuss the participants' experience with the SUSTAIN-DSD intervention.",[24],[443],"Differentiated Service Delivery","2025-11-19",{"date":446,"type":38},"2025-11-24",{"date":448,"type":38},"2025-11-14",{"date":450,"type":20},"2029-03-31",{"name":452,"class":95},"Brigham and Women's Hospital",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":143,"sex":16,"minAge":17,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":56,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":46},"100531842","phase-1-evaluation-of-safety-and-immunogenicity-of-ad26mos4hiv-and-ch505-tf-chtrimer-combination-in-healthy-adults-100531842","NCT06205056","Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults","Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults","RV591","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for participation:\n\n1. Male or female, aged 18 to 50 years, inclusive, at the time of enrollment\n2. Willing and able to read, sign, and date the informed consent form\n3. Demonstrates an understanding of the study with a passing score (90% or greater) on the TOU by the third attempt, before study-related procedures are performed\n4. Willing and able to comply with study requirements and be available to attend visits for the duration of study participation\n5. Must have the means to be contacted by telephone for the duration of study participation\n6. Willing to have photo or fingerprint taken for identification purposes\n7. At low risk for HIV acquisition per investigator assessment\n8. Agrees to refrain from donating blood or plasma outside of this study for at least the duration of study participation\n9. Healthy based on the physician investigator's clinical judgment after review of past medical history, medication use, vital signs, and an abbreviated physical examination\n\n   Note: Good health is defined by the absence of any medical condition described in the exclusion criteria in a participant with a normal abbreviated physical exam and vital signs. If the participant has a preexisting chronic condition not listed in the exclusion criteria, the condition cannot meet any of the following criteria:\n   1. first diagnosed within the 12 weeks prior to screening; or\n   2. worsening in terms of clinical outcome in the 24 weeks prior to screening; or\n   3. involves the need for medication that may pose a risk to the participant's safety or impede assessment of adverse events or immunogenicity if they participate in the study.\n\n   Note: Vital signs must be normal by Adverse Event Grading Scales, local normal ranges, or determined to be a normal variant by the physician investigator.\n\n   Note: An abbreviated physical exam differs from a complete exam in that it does not include a genitourinary and rectal exam.\n10. Laboratory criteria within 45 days prior to enrollment:\n\n    1. Hemoglobin ≥11.0 g\u002FdL for females; ≥12.5 g\u002FdL for males\n    2. White blood cells (WBC) range: 3,500-9,000 cells\u002Fmm\\^3\n    3. Platelets between 150,000 - 450,000 cells\u002FµL\n    4. Normal liver function: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤1.25x upper limit of normal\n    5. Serum creatinine ≤1.25x upper limit of normal\n    6. Urinalysis: blood and protein less than 1+ and negative glucose\n    7. Negative HIV serology Note: HIV serology testing will be done via enzyme immunoassay with confirmatory testing of reactive results through a repeat enzyme immunoassay followed by an antibody differentiation immunoassay. After the repeat enzyme immunoassay, if an antibody differentiation immunoassay cannot be done for any reason, then confirmatory testing will be done via Western Blot. HIV rapid testing will not be performed in this study.\n    8. Negative hepatitis B surface antigen (HbsAg)\n    9. Negative hepatitis C serology or negative hepatitis C RNA (viral load) if antibodies are detected Note: Each laboratory screening test that is out of acceptable range can be repeated one time during the screening window if there is a possible alternative explanation for the out of range value or if the out of range value is due to a temporary condition that resolves within the screening visit window. A second screening visit may be conducted outside of the initial screening visit window for volunteers who meet certain criteria if study enrollment and\u002For participant replacement is ongoing.\n11. Biological Male-Specific Criteria:\n\n    1. Must agree to refrain from donating sperm from screening until at least 12 weeks after the last study injection\n    2. Must agree to consistently use a method of contraception from screening until at least 12 weeks after the last study injection\n12. Biological Female-Specific Criteria:\n\n    1. Not pregnant within 12 weeks prior to screening, not pregnant or breastfeeding at screening, and not planning to become pregnant or breastfeed at any time from screening until 12 weeks after the last study injection\n    2. Must have a negative human chorionic gonadotropin (β-HCG) pregnancy test (urine) at screening and at timepoints throughout the study, if of childbearing potential\n    3. Must agree to consistently practice a highly effective method of contraception at least 45 days prior to enrollment and for 12 weeks after the final injection, if of childbearing potential\n\nExclusion Criteria:\n\nVolunteers will be excluded if any of the following apply:\n\n1. Body mass index (BMI) \\\u003C18.0 kg\u002Fm\\^2 and \\>35.1 kg\u002Fm\\^2\n2. Has a condition which affects immune function, including but not limited to:\n\n   1. Known or suspected congenital or acquired immunodeficiency\n   2. Diabetes mellitus type 1 or type 2 (including cases controlled with diet alone) Note: A history of isolated gestational diabetes is not an exclusion criterion.\n   3. Thyroid disease\n   4. Asplenia, defined as any condition resulting in the absence of a functional spleen\n   5. Conditions and diagnoses defined as potential immune-mediated medical conditions\n3. Has a history of other chronic or clinically significant diseases or medical conditions that in the opinion of the investigator would jeopardize the safety or rights of the participant Note: Includes but is not limited to sickle cell anemia, chronic hepatitis or cirrhosis, chronic urticaria, chronic cardiac disease, hypertension not controlled by medication, severe asthma, chronic pulmonary disease, renal failure, and lymphatic filariasis.\n4. Has a history of malignancy other than squamous cell or basal cell skin cancer, unless there has been definitive surgical and\u002For medical treatment that is considered to have achieved a cure\n5. Had major surgery (per the physician investigator's judgment) within the 28 days prior to screening or has plans to have major surgery during the study\n6. Has a personal or family history of a bleeding disorder, such as factor deficiency, coagulopathy, or platelet disorder requiring special precautions\n7. Has a personal or family history of a blood clotting disorder, such as thrombosis with thrombocytopenia syndrome (TTS), heparin-induced thrombocytopenia and thrombosis (HITT), deep vein thrombosis, pulmonary embolism, acute myocardial infarction, and stroke\n8. Has a condition known to increase risk of blood clotting, including but not limited to autoimmune disease, connective tissue and other inflammatory conditions, immobility, recent infection, and recent head trauma including cerebrovascular accidents (stroke)\n9. Hepatitis B surface antigen positive at any time in the past\n10. Untreated syphilis infection as confirmed by RPR or a similar quantitative nontreponemal test such as VDRL\n11. Prior receipt or plans to receive any of the following:\n\n    1. Chronic use of therapies that may modify immune response, such as high dose inhaled and sprayed corticosteroids (\\>440 µg\u002Ftwice daily doses of inhaled fluticasone equivalent) and systemic corticosteroids (\\>20 mg\u002Fday doses of prednisone equivalent for periods exceeding 10 days) within 14 days prior to enrollment or at any time during participation in this study Note: The following exceptions are permitted and will not exclude study participation: use of stable low\u002Fmedium doses (\\\u003C440 µg\u002Ftwice daily doses of inhaled fluticasone equivalent) of inhaled and sprayed corticosteroids, topical corticosteroids for an acute uncomplicated dermatitis; or a short course (duration of 10 days or less, or a single injection) of corticosteroid for a non-chronic condition (based on the physician investigator's clinical judgment) at least 14 days prior to enrollment in this study. Includes other medications, which, in the opinion of the physician investigator(s), will impact the participant's immune response.\n    2. Blood products within 120 days prior to enrollment or at any time during participation in this study\n    3. Immunoglobulins within 90 days prior to enrollment or at any time during participation in this study\n    4. Therapy for active tuberculosis within 90 days prior to enrollment, unless the therapy is considered to have achieved a cure, or at any time during participation in this study\n    5. Licensed or authorized vaccine from 30 days prior to enrollment until 42 days (6 weeks) after the last study injection Note: Participants may receive inactivated seasonal influenza vaccine or COVID-19 vaccine during their participation in this study but not within 14 days prior or 6 weeks after each study injection\n    6. Any investigational study products for conditions other than HIV within 90 days prior to enrollment or at any time during participation in this study\n    7. An investigational HIV vaccine or HIV antibody at any time prior to or during participation in this study\n    8. Medications that increase the risk of bleeding (warfarin, clopidogrel, ticagrelor, dabigatran, rivaroxaban, apixaban, heparin and other heparinoids) or blood clots (heparin in participants who have a prior history of heparin-induced coagulopathy) within 30 days prior to enrollment or at any time during participation in this study. \\[Note: Volunteers determined to be ineligible at screening due to receipt of the above listed substances may be re-screened once the applicable window of receipt has expired if study enrollment and\u002For participant replacement is ongoing\\].\n12. Has a known allergy or history of anaphylaxis or other serious reaction to a vaccine, vaccine component, or latex\n13. Current or planned participation in another study requiring blood draws or exposure to investigational or non-investigational vaccine\u002Fproduct (pharmaceutical or device) throughout the study period\n14. Has tattoos, scars, or other marks that would, in the opinion of the physician investigator, interfere with the assessment of the injection sites\n15. Current or history of substance abuse within 12 months prior to enrollment that, in the physician investigator's opinion, could interfere with reliable participation\n16. In the physician investigator's opinion, is unable to communicate reliably, is unlikely to adhere to study requirements, or has a condition that would limit completion of the study\n17. Any other chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the participant or potentially impairs immune response or threatens conduct of the study according to protocol\n18. Study site employee\n\nFinal evaluation of eligibility will be based on the medical judgment of the physician investigator.","50 Years",{"count":463,"type":20},78,[58],"This is a Phase I, randomized, double-blind, placebo-controlled clinical study to define the safety and immunogenicity resulting from a rapid dose-escalating vaccination schedule as compared to that of a co-administered, dose-consistent vaccination schedule. Participants randomized to receive vaccines will get either dose-consistent injections of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV or rapid, dose-escalating injections of CH505 TF chTrimer+ALFQ with an Ad26.Mos4.HIV prime, followed by dose-consistent injection of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV",[24],"2025-10-01",{"date":469,"type":38},"2025-10-07",{"date":471,"type":38},"2024-01-30",{"date":184,"type":20},{"name":474,"class":475},"U.S. Army Medical Research and Development Command","FED",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":46},"100451512","tulane-abdominal-transplant-institute-tati-of-solid-organ-transplantation-of-hiv-positive-recipients-from-hiv-positive-donors-100451512","NCT05159466","Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors","Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors (TATI HOPE Act)","Recipient Criteria\n\nInclusion Criteria:\n\n* Participant meets standard listing criteria for transplant.\n* Greater than or equal to 18 years of age.\n* Participant has documented HIV infection using an FDA-licensed, approved, or cleared test device(s).\n* CD4+ T-cell count ≥200\u002FμL within 16 weeks prior to transplant; any patient with history of Opportunistic Infections must have a CD4 positive T-cell count ≥200\u002FuL.\n* HIV RNA less than 50 copies\u002FmL and on a stable antiretroviral regimen.\n* No evidence of active opportunistic complications of HIV infection.\n* On a stable antiretroviral regimen. Participants unable to tolerate ART due to organ failure may still be considered eligible if the study team is confident there will be a safe, tolerable, and effective antiretroviral regimen once organ function is restored after transplantation.\n* No history of primary CNS lymphoma or progressive PML\n\nExclusion Criteria:\n\n* Participant has concomitant conditions that, in the judgment of the investigators, would preclude transplantation or immunosuppression.\n* Less than 18 years of age.\n* Requires multi-organ transplantation.\n* Participant is pregnant or breastfeeding.\n* Participant has a history of progressive multifocal leukoencephalopathy (PML), chronic intestinal cryptosporidiosis of \\> 1 month duration, or primary CNS lymphoma.\n* Participant has a history of any neoplasm except for the following: resolved Kaposi's sarcoma, in situ anogenital carcinoma, adequately treated basal or squamous cell carcinoma of the skin, solid tumors (except primary CNS lymphoma) treated with curative therapy and disease free for more than 5 years. History of renal cell carcinoma requires disease-free state for 2 years. History of leukemia and disease free duration will be per site policy.\n* Participants who are unable or unwilling to provide informed consent.\n\nDonor Criteria Deceased Donor Criteria\n\n1. Must meet all clinical criteria for HIV-uninfected organ donors.\n2. No evidence of invasive opportunistic complications of HIV infection.\n3. Pre-implant donor organ biopsy showing no disease process that would put the recipient at increased risk of rapid progression to end-stage organ failure, to be stored for the duration of the study.\n4. Donor has documented HIV infection (by any licensed ELISA and confirmation by Western Blot, positive HIV ab IFA, or history of detectable HIV-1 RNA) from a CLIA approved laboratory.\n5. If known history of HIV infection and prior antiretroviral therapy, the study team must describe the anticipated post-transplant antiretroviral regimen(s) to be prescribed for the recipient and justify its conclusion that the regimen will be safe, tolerable and effective.\n6. Pre-implant donor organ biopsy to be stored, at a minimum, for the duration of the study (or at least 5 years).\n7. For donors with newly diagnosed\u002Fdiscovered HIV-1 infection, any HIV-1 RNA viral load is allowed assuming the donor meets other criteria and the HIV\u002FTransplant Infectious Diseases team is able to predict a tolerable and effective ART regimen for the recipient.\n8. If there is any history of documented antiretroviral resistance in the donor by medical chart review, the HIV\u002FTransplant Infectious Diseases team is able to predict a tolerable and effective ART regimen for the recipient.\n9. Donors with documented chronic hepatitis C virus (HCV+) co-infection (detectable HCV nucleic acid using any licensed assay in a CLIA certified lab) can be used only for HCV+ participants.\n\nLiving Donor Criteria\n\n1. Greater than or equal to 18 years of age\n2. Donor meets all clinical criteria to be a living donor other than being HIV positive.\n3. Donor has consented to participate as a HIV-Positive Donor under the separate Addendum protocol.\n4. Documented HIV infection using an FDA-licensed, approved, or cleared test device.\n5. Well-controlled HIV infection, as evidenced by:\n\n   1. CD4+ T-cell count ≥500\u002FmL for the 6-month period preceding donation.\n   2. Fewer than 50 copies\u002FmL of HIV- 1 RNA detectable by ultrasensitive or real-time polymerase chain reaction (PCR) assay.\n6. No evidence of invasive opportunistic complications of HIV infection\n7. A kidney biopsy showing no evidence of a disease process that would put the donor at increased risk of progressing to end-stage organ failure after donation, or that would present a risk of poor graft function to the recipient.\n8. A complete history of ART regimens and ART resistance.\n9. The study team must be able to predict a safe, tolerable, and effective regimen to be prescribed for the recipient based on the donor's current ART regimen as well as the donor's history of ART resistance.",{"count":484,"type":20},30,"The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH), published Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. All such transplants must occur under an institutional review board (IRB) approved research protocol that is compliant with federal regulations governing human subjects research. This is an investigator-initiated, observational prospective study of solid organ transplantation utilizing HIV-positive donors in HIV positive recipients. Stable HIV-infected adults in need of a solid organ transplant (kidney) who meet standard and study specified HIV criteria for organ transplantation will be offered enrollment in the study. Deceased donors (kidney) and living donors (kidney) will be utilized in this protocol.\n\nThe goal of this research is to increase knowledge about the safety, efficacy, and effectiveness of solid organ transplantation (SOT) utilizing HIV-positive donors in HIV-positive recipients.",[24,487],"End Stage Renal Disease",[489,490,491,492,62],"Organ donor","Organ recipient","Kidney Transplant","HOPE Act","2025-09-30",{"date":495,"type":38},"2025-10-02",{"date":497,"type":38},"2021-11-15",{"date":499,"type":20},"2026-11",{"name":501,"class":95},"Tulane University",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":56,"phases":510,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":383},"100499691","phase-3-vpsf-m-for-tobacco-cessation-in-hiv-care-in-india-100499691","NCT05786547","V+PSF-M for Tobacco Cessation in HIV Care in India","Varenicline and Mobile Behavioral Assistance for Tobacco Cessation in HIV Care in India","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Confirmed HIV diagnosis\n* Self-reported current smoking or dual tobacco use verified either by exhaled carbon monoxide ≥7 ppm, or by positive qualitative cotinine point-of-care test\n* Able to read at 6th grade level or greater and speak Tamil, Telugu or English\n* Able to use varenicline safely based on evaluation by primary provider at VHS\n* Women of childbearing potential who consent to use a medically approved method of contraception or abstain from intercourse while taking study medication and for one month after.\n* Ready to quit or interested in quitting\n\nExclusion Criteria:\n\n* Pregnant or planning to become pregnant in the next 6 months\n* Breastfeeding\n* Myocardial infarction in past 30 days or unstable angina\n* History of liver or kidney failure\n* Alanine aminotransferase and Aspartate aminotransferase \\> 2 times upper limit of normal or creatinine clearance \\\u003C50 in past 6 months\n* History of suicide attempt\n* Current suicidal ideation\n* Untreated or unstable major depressive disorder\n* History of psychosis or on anti-psychotic medications\n* Cognitive impairment limiting ability to consent\n* Allergy to varenicline",{"count":262,"type":20},[264],"The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV).\n\nThe study interventions used in this research study are:\n\n* Positively Smoke Free - Mobile (PSF-M) (mobile behavioral program)\n* Varenicline (or Chantix, apovarenicline, Champix or Nocrav)",[24,513,514],"Smoking Cessation","Smoking, Tobacco",[24,513,514],"2025-06-13",{"date":518,"type":38},"2025-06-15",{"date":520,"type":38},"2024-01-02",{"date":522,"type":20},"2026-07-22",{"name":227,"class":95},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":16,"minAge":530,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":56,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":383},"100488649","text-education-about-cardiovascular-health-and-hiv-teach-hiv-100488649","NCT05642858","Text Education About Cardiovascular Health and HIV (TEACH-HIV)","Inclusion Criteria:\n\n* HIV positive\n* At least 40 years of age\n* English-speaking\n\nExclusion Criteria:\n\n* Existing clinical atherosclerotic cardiovascular disease (ASCVD)\n* Pregnant\n* Unwilling\u002Funable to provide informed consent\n* Does not own a smartphone","40 Years",{"count":532,"type":20},260,[148],"The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).",[62,24,536,537],"Cardiovascular Diseases","Atherosclerosis","2025-06-04",{"date":540,"type":38},"2025-06-08",{"date":542,"type":38},"2023-03-12",{"date":544,"type":20},"2026-07-01",{"name":546,"class":95},"University of California, San Francisco",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":143,"sex":16,"minAge":17,"maxAge":364,"enrollmentInfo":555,"targetDuration":4,"studyType":56,"phases":557,"briefSummary":558,"conditions":559,"keywords":565,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":575,"locationsCount":46},"100459767","phase-4-immunogenicity-of-gardasil-9-hpv-vaccine-in-people-living-with-hiv-100459767","NCT05266898","Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV","Prospective Observational Immunogenicity Trial of Gardasil-9 HPV Vaccine in People Living With Adequately Managed HIV","AGO-Gard","Inclusion Criteria:\n\n* HIV seropositive\n* immune intact (CD4+ T cell count in peripheral blood \\>200 cells\u002Fml)\n* HIV controlled (peripheral blood HIV viral load \\\u003C1,000 genome copies\u002FmL)\n* Stable on antiretroviral regimen for ≥3 months\n* Gardasil-9 naive and age ≤45 OR\n* documented receipt of 3 doses of Gardasil-4 or Gardasil-9 HPV vaccine\n\nExclusion Criteria:\n\n* Medical contraindication for vaccination (vaccine-naive arm only)\n* Women who are pregnant\n* Acute illness\n* Taking chronic steroids, \\>0.5mg\u002Fkg prednisone or equivalent\n* Taking immune modulating medications\n* Received blood transfusion\u002Fblood products within the past 6 months\n* Recipients of other vaccine products within the past month\n* Inability to provide informed written consent",{"count":556,"type":20},250,[342],"The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection.\n\nThe secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, and to determine the protection afforded by Gardasil vaccine over time in previously vaccinated adults living with HIV.\n\nThe clinical hypothesis is that adults with virologically controlled HIV mount a serum antibody response to the nonavalent HPV vaccine that is comparable to HIV negative counterparts. We also postulate that HPV vaccination will provide short-term clinical benefit against HPV infections and disease associated with vaccine genotypes and continuing protection against vaccine genotypes of HPV over time.",[560,24,561,562,563,175,564],"Papillomavirus Vaccines","Papillomavirus Infection","Serology","Cervical Intraepithelial Neoplasia","Oral Cavity Infection",[566,567,568],"Gardasil-9 HPV vaccine","human papillomavirus","human immunodeficiency virus","2025-04-15",{"date":571,"type":38},"2025-04-18",{"date":573,"type":38},"2022-11-30",{"date":184,"type":20},{"name":576,"class":95},"Louisiana State University Health Sciences Center in New Orleans",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":56,"phases":586,"briefSummary":587,"conditions":588,"keywords":589,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":4},"100584423","impact-of-nmn-supplementation-on-cd4-t-cell-recovery-in-hiv-patients-with-immunological-failure-100584423","NCT06889142","Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure","Proof-of-Concept Study: Investigating the Impact of NMN Supplementation on CD4+ T Cell Recovery in Virologically Suppressed HIV Patients With Immunological Failure","Inclusion Criteria:\n\n* HIV-infected adults aged 18 years or older\n* Virologically suppressed on ART documented with two negative viral loads separated by at least 6 months\n* Confirmed diagnosis of immunological failure (CD4+ T cell count \\\u003C350 cells\u002FµL 2 years after effective ART initiation)\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Active opportunistic infections\n* Known allergies or sensitivities to NMN or any components of the NMN supplement\n* Current or recent use of other supplements or medications known to affect NAD+ metabolism (Niacin, NR, NMNH, etc.)\n* Pregnancy or breastfeeding\n* Significant liver or kidney disease\n* Active malignancy\n* History of uncontrolled substance abuse\n* Severe medical conditions that might interfere with study participation\n* Unable to consent",{"count":585,"type":20},7,[148],"This proof-of-concept study aims to investigate the potential impact of supplementing with Nicotinamide Mononucleotide (NMN), a direct precursor of NAD+ on CD4+ T cell recovery in virologically suppressed HIV patients experiencing immunological failure on ART. We hypothesize that NMN supplementation will increase intracellular NAD+ levels, thereby improving CD4+ T cell function and potentially reversing immunological failure. A small cohort of patients will be recruited to evaluate the primary outcome of change in CD4+ T cell count from baseline to the end of the study period after receiving NMN daily for 12 weeks. Secondary outcomes including safety and tolerability, impact on pro-inflammatory markers, increase in NAD+ levels, immune activation markers and change in quality of life questionnaire scores. Patients will participate in two in person visits including a baseline and end of study with two telephone encounters. Patients will take 1,000mg NMN daily for a total of 12 weeks during which they will keep a daily log of doses taken and any side effects experienced. At all visits labs and quality of life questionnaire will be completed with complete physical exam to be done at baseline and end of study visit.",[24],[62,590,591,592,593,594],"immunologic failure","proof of concept","CD4+ T cell recovery","immunological non-responders","Nicotinamide Mononucleotide","2025-03-31",{"date":597,"type":38},"2025-04-03",{"date":599,"type":20},"2025-04",{"date":601,"type":20},"2025-07",{"name":603,"class":95},"TriHealth Inc.",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":610,"enrollmentInfo":611,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":621,"locationsCount":46},"100548743","use-of-long-acting-injectable-cabotegravirrilpivirine-for-the-treatment-of-hiv-in-belgium-100548743","NCT06424964","Use of Long-Acting Injectable Cabotegravir\u002FRilpivirine for the Treatment of HIV in Belgium","Inclusion Criteria:\n\n* HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB\u002FRPV between September 1, 2021, and March 31, 2024.","99 Years",{"count":612,"type":20},600,"This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.\n\nPrimary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir\u002Frilpivirine (CAB\u002FRPV) for the treatment of HIV\n\nSecondary outcomes\n\n• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis",[24],"2025-02-04",{"date":617,"type":38},"2025-02-05",{"date":619,"type":38},"2025-01-13",{"date":601,"type":20},{"name":622,"class":95},"Belgian Research on AIDS and HIV Consortium",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":56,"phases":632,"briefSummary":633,"conditions":634,"keywords":636,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":650,"leadSponsor":652,"locationsCount":46},"100562481","computerized-cognitive-rehabilitation-of-patients-with-cognitive-deficits-due-to-the-human-immunodeficiency-virus-100562481","NCT06603727","Computerized Cognitive Rehabilitation of Patients With Cognitive Deficits Due to the Human Immunodeficiency Virus","Combined Cognitive and Physical Training for the Neurorehabilitation of Patients With Cognitive Deficits Due to the Human Immunodeficiency Virus: a Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of an HIV infection\n* Undetectable HIV load in the serum (\\\u003C50 copies\u002FmL) over the last 6 months prior to study inclusion.\n* Z-score ≤ -1.0 in at least one of the three following tests:\n\n  * Color Trail Test (CTT) Flexibility Index\n  * subtest Code of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV)\n  * subtest Digit Span of the WAIS-IV\n* Z-score ≤ -1.0 in at least one of the following tests:\n\n  * Symbol Digits Modalities Test (SDMT)\n  * Brief Visuospatial Memory Test Revised (BVMT-R)\n  * CTT Flexibility Index\n  * Stroop Color-Word interference test\n\nExclusion Criteria:\n\n* Clinically defined cause for cognitive deficits other than HIV\n* Diagnosis of severe depression according to a cut-off score of ≥ 27 of the Center for epidemiological studies - depression questionnaire (CES-D; Metral et al., 2020; Radloff, 1977)\n* Diagnosis of HIV-associated dementia according to the Frascati Critera (Antinori et al., 2007)\n* Current psychotic symptoms according to the Mini-International Neuropsychiatric Interview (M.I.N.I. - L, Sheehan et al., 1998) subscale of psychotic symptoms\n* Antidepressive, anxiolytic or cART medication that has been changed over the last month\n* Thoracic pain and\u002For heart palpitations at rest, during or following a physical effort (based on self-report)\n* For patients without known and clinically stable cardio-vascular disease: abnormal rest electrocardiogram readings suggestive of second degree type Mobitz or third degree atrioventricular blocking, pathological repolarization (T-wave inversion, ST elevation, abnormal QT lengthening in at least two corresponding leads), or typical features of channelopathies\n* Premature termination of maximal effort test due to cardiac problems\n* Falls in the past 12 weeks as evaluated in the enrolment interview (Hopkins Falls Grading Scale, Grade \\>1)\n* High risk of falling according a cutoff score \\> 15 sec in the Four Square Step Test (Dite \\& Temple, 2002)\n* Incapacity to discriminate colors or insufficient visual acuity that cannot be corrected\n* Incapacity or unwillingness to provide informed consent\n* Insufficient knowledge of French to understand and follow instructions",{"count":631,"type":20},24,[148],"WHO: 24 participants with cognitive deficits due to a Human Immunodeficiency Virus (HIV) infection, able to engage in moderate physical activity.\n\nWHY: The Human Immunodeficiency Virus is known to cause deficits in cognitive function, even under effective pharmacological viral load suppression. Cognitive dysfunction in patients with HIV is frequent and has a detrimental impact on their everyday personal and professional life. The purpose of this study is to evaluate two sets of computerized exercises combining cognitive and physical effort to see if they can improve executive function in patients with an HIV infection.\n\nWHAT: Study participants first undergo cognitive and physical assessments. Additional questionnaires will assess mood, everyday life cognition, function and quality. This will be followed by a 6 week training period with 2 training sessions a week. The effect of the physical and cognitive training will be measured in a post-training evaluation session. Six months after completion of the training, the study will evaluate cognitive and physical abilities of participants to study long-term effects of the respective training program.\n\nWHERE: Both the evaluation and the training sessions will be conducted on the premises of the Lausanne University Hospital (Rue du Bugnon 46, 1005 Lausanne, Switzerland)",[24,635],"Cognitive Dysfunction",[637,638,639,640,641,642,643,644,645],"HIV Infections","Communicable Diseases","Neurological Rehabilitation","Cognitive Behavioural Therapy","Exercise Therapy","Nervous System Diseases","Neurocognitive Disorders","Cognition Disorders","Mental Disorders","2024-09-16",{"date":648,"type":38},"2024-09-19",{"date":223,"type":20},{"date":651,"type":20},"2026-08-31",{"name":653,"class":95},"Centre Hospitalier Universitaire Vaudois"]